Selinexor for myelofibrosis with low platelets (no prior JAK inhibitors)
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a drug called selinexor (taken by mouth) for people with myelofibrosis who have low to moderate platelet counts and haven't tried JAK inhibitors yet. It aims to shrink the spleen and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with myelofibrosis (including after a blood disorder called polycythemia vera or essential thrombocythemia).
- Your spleen is enlarged (at least 450 cm³ on an MRI or CT scan).
- Your platelet count is 50,000 or higher (without a transfusion in the last 7 days).
- You have not been treated with a JAK inhibitor (like ruxolitinib or fedratinib) before.
- You are not eligible for a stem cell transplant (bone marrow transplant).
- You have symptoms from myleofibrosis that affect your daily life, like fever, night sweats, or bone pain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, selinexor and pacritinib, for people with myelofibrosis who have not had previous JAK inhibitor treatment and have low red blood cells (anemia) or low platelets. The goal is to see if these drugs can help improve symptoms and reduce spleen size while being safe for patients with cytopenias.
This trial tests two oral medications, momelotinib and ruxolitinib, to see which works better for people with newly diagnosed myelofibrosis who also have low blood cell counts. You may be able to join if your spleen is enlarged and you haven't had prior treatment with certain drugs.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests a new drug called RVU120 for people with myelofibrosis that has not responded well to standard JAK inhibitor treatment. It aims to shrink the spleen and improve symptoms.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This trial tests a drug called selinexor to help shrink blood cell counts in patients with rare bone marrow disorders (polycythemia vera, essential thrombocythemia, or primary myelofibrosis) who cannot tolerate or are unwilling to use standard treatments. The goal is to reduce symptoms like extreme platelet counts, high white blood cell counts, or enlarged spleen.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.